This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cornell University. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Linda Vahdat: Innovator in Cancer Prognostics
Introduction
Linda Vahdat is a prominent inventor based in Wilton, CT (US). She has made significant contributions to the field of cancer research, particularly in the area of prognostic indicators for cancer progression and relapse. Her innovative work has the potential to improve patient outcomes through early detection and monitoring.
Latest Patents
Linda Vahdat holds a patent titled "Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer." This patent outlines methods for determining cancer progression or relapse in subjects at risk. The methods involve obtaining a sample from the subject, measuring the levels of VEGFR1 hematopoietic progenitor cells (HPCs) and/or VEGFR2 endothelial progenitor cells (EPCs), and conducting additional measurements over time. A surge in the levels of these cells indicates an increased risk of cancer progression or relapse.
Career Highlights
Linda Vahdat is affiliated with Cornell University, where she continues her research and development in cancer prognostics. Her work is recognized for its innovative approach to understanding cancer dynamics and improving patient care.
Collaborations
Linda collaborates with notable colleagues, including Maureen Lane and Vivek Mittal, who contribute to her research efforts and enhance the impact of her work.
Conclusion
Linda Vahdat's contributions to cancer research through her innovative patent highlight her role as a key inventor in the field. Her work not only advances scientific understanding but also holds promise for improving cancer patient management.